Literature DB >> 3310604

Development and use of a natural history data base of breast cancer studies.

T E Moon1, S E Jones, G Bonadonna, P Valagussa, T Powles, A Buzdar, E Montague.   

Abstract

Pretreatment information, type of treatment, and longitudinal follow-up on 1,971 patients with operable breast cancer were used to establish a breast cancer natural history data base (NHDB). Data were available for 957 patients with stage I (node-negative) breast cancer and 1,014 stage II (node-positive) patients. In women with negative nodes, information was available on 759 patients treated at the Milan National Cancer Institute and 188 patients treated at the Royal Marsden Hospital. After adjustment for differences in the distribution of patient prognostic factors, relapse-free survival and overall survival were not significantly different. Of the 1,014 node-positive patients, 540 were treated at the Milan National Cancer Institute, 258 at the Royal Marsden, and 216 at the M. D. Anderson Hospital. Relapse-free survival and overall survival did not significantly differ between Milan patients and those treated at the Royal Marsden Hospital. However, M. D. Anderson Hospital patients did have significantly better relapse-free and overall survival. In each institution, outcome was consistently most dependent on the number of involved axillary lymph nodes and tumor size. Also, similar patterns of survival were observed for each of the institutions. The development of an NHDB can be of value in the identification and evaluation of consistency of prognostic factors, permitting improved comparisons between clinical trials. The development of such a natural history data base (NHDB) provides a reference for assessing the impact of different adjuvant chemotherapy programs, and aids in the design of new protocols.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3310604     DOI: 10.1097/00000421-198710000-00006

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  8 in total

1.  The impact of lymph node metastases on the survival of breast cancer patients with ten or more positive lymph nodes.

Authors:  A Tsuchiya; M Kanno; R Abe
Journal:  Surg Today       Date:  1997       Impact factor: 2.549

Review 2.  Systemic adjuvant therapy for node-negative breast cancer.

Authors:  A D Ginsburg; D J Perrault; K I Pritchard; G P Browman; P B McCulloch; J Skillings
Journal:  CMAJ       Date:  1989-09-01       Impact factor: 8.262

3.  Long term prognostic value of Nottingham histological grade and its components in early (pT1N0M0) breast carcinoma.

Authors:  S Frkovic-Grazio; M Bracko
Journal:  J Clin Pathol       Date:  2002-02       Impact factor: 3.411

4.  Tumour size and vascular invasion predict distant metastasis in stage I breast cancer. Grade distinguishes early and late metastasis.

Authors:  P J Westenend; C J C Meurs; R A M Damhuis
Journal:  J Clin Pathol       Date:  2005-02       Impact factor: 3.411

Review 5.  Response to treatment of breast cancer.

Authors:  J L Berenberg
Journal:  Breast Cancer Res Treat       Date:  1991-05       Impact factor: 4.872

6.  Survival in 12,653 breast cancer patients with extensive axillary lymph node metastasis in the anthracycline era.

Authors:  Shannon H Beal; Steve R Martinez; Robert J Canter; Steven L Chen; Vijay P Khatri; Richard J Bold
Journal:  Med Oncol       Date:  2010-01-05       Impact factor: 3.064

7.  Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI study.

Authors:  Stefania Gori; Matteo Clavarezza; Salvatore Siena; Jennifer Foglietta; Emiliana Tarenzi; Monica Giordano; Annamaria Molino; Claudio Graiff; Vittorio Fusco; Oscar Alabiso; Editta Baldini; Teresa Gamucci; Giuseppe Altavilla; Davide Dondi; Marco Venturini
Journal:  BMC Cancer       Date:  2012-04-30       Impact factor: 4.430

8.  Predictors of long-term outcome following high-dose chemotherapy in high-risk primary breast cancer.

Authors:  G Somlo; J F Simpson; P Frankel; W Chow; L Leong; K Margolin; R Morgan; J Raschko; S Shibata; S Forman; N Kogut; M McNamara; A Molina; E Somlo; J H Doroshow
Journal:  Br J Cancer       Date:  2002-07-29       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.